HAEMONETICS CORP - Common Stock (HAE)

Q1 2019 13F Holders as of 31 Mar 2019

Type / Class
Equity / Common Stock
Shares outstanding
47,898,935
Total 13F shares
51,283,498
Share change
+821,113
Total reported value
$4,486,016,605
Put/Call ratio
28%
Price per share
$87.48
Number of holders
253
Value change
+$59,010,778
Number of buys
124
Number of sells
149

Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q1 2019

As of 31 Mar 2019, HAEMONETICS CORP - Common Stock (HAE) was held by 253 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 51,283,498 shares. The largest 10 holders included BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, Jackson Square Partners, LLC, Neuberger Berman Group LLC, Capital Research Global Investors, HealthCor Management, L.P., and AQR CAPITAL MANAGEMENT LLC. This page lists 253 institutional shareholders reporting positions in this security for the Q1 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.